Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes, Diabetes Mellitus, Type 2
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of…
- Trial name
- LEAD-2 (NCT00318461)
- Testing
- liraglutide, metformin, glimepiride
- Where
- 190 sites in Argentina, Australia and 18 more
- Volunteers
- 1,091 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Japanese Phase 1 Multiple Ascending Dose Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-823778 in healthy Japanese subjects and Japanese patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01515202
- Testing
- BMS-823778
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00184613
- Testing
- pump, insulin glargine, insulin aspart
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
This trial is conducted in Asia. The aim of the trial is to compare the effect on glycaemic control of biphasic insulin aspart 30 twice daily with two different dosage split regimens for Chinese subjects with type 2 diabetes who…
- Trial name
- NCT01278160
- Testing
- biphasic insulin aspart 30, metformin
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Non-Insulin-Dependent
NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes
The purpose of this research study is to investigate the mechanism of action of a new investigational medication (drug), NNC 90-1170, which is being developed for the treatment of type 2 diabetes (adult onset type of diabetes.
- Trial name
- NCT00013910
- Testing
- NNC 90-1170
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Diabetes Mellitus, Type 2, Diabetes Mellitus
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effectiveness and safety of 12 weeks of treatment with R256918 in patients with Type 2 Diabetes Mellitus who are taking metformin.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Endocrine System Diseases, Nutritional and Metabolic Diseases
- Trial name
- NCT00672386
- Testing
- JNJ16269110, Metformin, Dietary Counseling
- Where
- 62 sites in Belgium, Denmark and 9 more
- Volunteers
- 352 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
This is a phase I, open-label, fixed-sequence study in healthy Chinese subjects, performed at a single study centre. Cohort A will assess the Pharmacokinetic (PK) profile of rongliflozin when administered alone and the…
- Trial name
- NCT05497674
- Testing
- Rongliflozin, Rifampin, Probenecid
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Diabetes Mellitus, Type 2
Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects
KDT501 is an orally administered product designed to help control impaired glucose and insulin regulation in patients with insulin resistance.
- Trial name
- NCT02444910
- Testing
- KDT501
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- KinDex Pharmaceuticals, Inc.
Healthy
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
The purpose of this study is to assess the bioequivalence (similarity of the drug amount in blood among the formulations) of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin…
- Trial name
- NCT02077803
- Testing
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes.
- Trial name
- FOCUS (NCT03811561)
- Testing
- Semaglutide
- Where
- 230 sites in United States, Brazil and 17 more
- Volunteers
- 1,500 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System
A multi-center, single-arm, open-label study to evaluate the safety and effectiveness of the EndoBarrier Gastrointestinal Liner System liner on glycemic control in control subjects from study #09-1 who are not treatment failures…
- Trial name
- OLE (NCT02293720)
- Testing
- EndoBarrier
- Sponsor
- Morphic Medical Inc.
Diabetes Mellitus, Type 2
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes.
- Trial name
- SWITCH PRO (NCT03687827)
- Testing
- Insulin degludec, Insulin glargine
- Where
- 67 sites in United States, Canada and 4 more
- Volunteers
- 498 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00476931
- Testing
- SB-509
- Where
- 20 sites in United States, Mexico
- Volunteers
- 91 people
- Sponsor
- Sangamo Therapeutics
Type 2 Diabetes Mellitus
Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus
This is a 2-arm, single-blind, crossover, placebo-controlled clinical study, with 24 weeks of therapy to evaluate the efficacy and safety of DbXell in improving metabolic control in patients with Type 2 Diabetes that is mildly…
- Trial name
- NCT02123732
- Testing
- DbXell
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Laniado Hospital
Type 1 Diabetes Mellitus
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
Each subject will be allocated to 2 periods of 3 months of once daily dosing with either liraglutide (1.2 mg) or placebo treatment (in random sequence) as add on to usual intensive insulin treatment.
- Trial name
- NCT02408705
- Testing
- Liraglutide, Mixed Meal Tolerance Test with paracetamol
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Medical University of Graz
Type2diabetes, Endothelial Dysfunction
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes…
- Trial name
- NCT05831644
- Testing
- C21
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Vicore Pharma AB
Type 2 Diabetes Mellitus
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are…
- Trial name
- NCT01555164
- Testing
- Ranolazine, Metformin, Diet
- Where
- 146 sites in United States, Canada and 9 more
- Volunteers
- 442 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00330200
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.
- Trial name
- BOOST™ (NCT01272193)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 50 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S